| Item | Cat. No. | Application | Isotype |
| Anti-Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-II mAbs [Miromavimab Biosimilar] (MAB | MABL-4942 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-FOLR1 mAbs [Mirvetuximab Biosimilar] (MABL-4943) | MABL-4943 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-B7H3/CD276 mAbs [Mirzotamab Biosimilar] (MABL-4944) | MABL-4944 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-MSLN mAbs [Misitatug Biosimilar] (MABL-4945) | MABL-4945 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-TNFRSF5/CD40 mAbs [Mitazalimab Biosimilar] (MABL-4946) | MABL-4946 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-ADPRC1/CD38 mAbs [Modakafusp Biosimilar] (MABL-4947) | MABL-4947 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-EGFR/ERBB1/HER1 mAbs [Modotuximab Biosimilar] (MABL-4948) | MABL-4948 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-SIRPA mAbs [Moflerafusp Biosimilar] (MABL-4949) | MABL-4949 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CCR4/CD194 mAbs [Mogamulizumab Biosimilar] (MABL-4950) | MABL-4950 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-KLRC1 mAbs [Monalizumab Biosimilar] (MABL-4951) | MABL-4951 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-CD3E;MS4A1/CD20 mAbs [Mosunetuzumab Biosimilar] (MABL-4952) | MABL-4952 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa;Kappa |
| Anti-Respiratory Syncytial Virus Glycoprotein F mAbs [Motavizumab Biosimilar] (MABL-4953) | MABL-4953 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-SARS-CoV-2 Spike RBD mAbs [Masavibart Biosimilar] (MABL-4923) | MABL-4923 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-EGFR/ERBB1/HER1 mAbs [Matuzumab Biosimilar] (MABL-4924) | MABL-4924 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CSF2RA/CD116 mAbs [Mavrilimumab Biosimilar] (MABL-4925) | MABL-4925 | ELISA, FACS, Functional assay, in vivo binding | G4, Lambda |
| Anti-NT5E/CALJA/CD73 mAbs [Mavrostobart Biosimilar] (MABL-4926) | MABL-4926 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-Rabies Virus Spike Glycoprotein G mAbs [Mazorelvimab Biosimilar] (MABL-4927) | MABL-4927 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-AXL/UFO mAbs [Mecbotamab Biosimilar] (MABL-4928) | MABL-4928 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-Non-Binding mAbs [Melredableukin Biosimilar] (MABL-4929) | MABL-4929 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL1RL1/ST2 mAbs [Melrilimab Biosimilar] (MABL-4930) | MABL-4930 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
